receptors Archives - World Asthma Foundation

August 4, 2015

Expression of adenosine receptors in monocytes from patients with bronchial asthma.

Expression of adenosine receptors in monocytes from patients with bronchial asthma.

Biochem Biophys Res Commun. 2015 Jul 29;

Authors: Yuryeva K, Saltykova I, Ogorodova L, Kirillova N, Kulikov E, Korotkaya E, Iakovleva Y, Feoktistov I, Sazonov A, Ryzhov S

Abstract
Adenosine is generated from adenosine triphosphate, which is released by stressed and damaged cells. Adenosine levels are significantly increased in patients with bronchial asthma (BA) and mediate mast cell degranulation and bronchoconstriction. Over the last decade, increasing evidence has shown that adenosine can modulate the innate immune response during monocytes differentiation towards mature myeloid cells. These adenosine-differentiated myeloid cells, characterized by co-expression of monocytes/macrophages and dendritic cell markers such as CD14 and CD209, produce high levels of pro-inflammatory cytokines, thus contributing to the pathogenesis of BA and chronic obstructive pulmonary disease. We found that expression of ADORA2A and ADORA2B are increased in monocytes obtained from patients with BA, and are associated with the generation of CD14(pos)CD209(pos) pro-inflammatory cells. A positive correlation between expression of ADORA2B and IL-6 was identified in human monocytes and may explain the increased expression of IL-6 mRNA in asthmatics. Taken together, our results suggest that monocyte-specific expression of A2 adenosine receptors plays an important role in pro-inflammatory activation of human monocytes, thus contributing to the progression of asthma.

PMID: 26232643 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

December 8, 2014

Two distinct leukotriene B4 receptors, BLT1 and BLT2.

Two distinct leukotriene B4 receptors, BLT1 and BLT2.

J Biochem. 2014 Dec 4;

Authors: Yokomizo T

Abstract
Leukotriene B4 (LTB4) is a potent inflammatory mediator derived from arachidonic acid. Two G protein-coupled receptors for LTB4 have been identified: a high-affinity receptor, BLT1, and a low-affinity receptor, BLT2. Both receptors mainly couple to pertussis toxin-sensitive Gi-like G proteins and induce cell migration. 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (12-HHT) was identified to bind BLT2 with higher affinity than LTB4. Expression of BLT1 was confirmed in type 1 helper T cells (Th1), Th2 cells, Th17 cells, effector CD8(+) T cells, dendritic cells, and osteoclasts in addition to granulocytes, eosinophils, and macrophages, and BLT1-deficient mice showed greatly reduced phenotypes in models of various inflammatory diseases, including peritonitis, bronchial asthma, rheumatoid arthritis, atherosclerosis, and osteoporosis. In mice, BLT2 expression is restricted to intestinal epithelial cells and epidermal keratinocytes. BLT2-deficient mice showed enhanced colitis after administration of dextran sulfate, possibly due to reduced intestinal barrier function. An aspirin-dependent reduction in 12-HHT production was responsible for delayed skin wound healing, showing that the 12-HHT/BLT2 axis also plays an important role in skin biology. BLT1 and BLT2 are therefore potential targets for the development of novel drugs.

PMID: 25480980 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

January 8, 2014

Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.

Condition: Asthma
Intervention: Other: TLRs
Sponsor: Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
Completed – verified January 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

August 1, 2013

Inflammation switch for allergic asthma, COPD found in leukotriene receptors – ScienceBlog.com (blog)

Inflammation switch for allergic asthma, COPD found in leukotriene receptors
ScienceBlog.com (blog)
Japanese researchers have made a new step toward understanding why—and how to stop—runaway inflammation for both chronic obstructive pulmonary disorder (COPD) and allergic asthma. In a new report appearing in the August 2013 issue of The …

and more »

View full post on asthma – Google News

May 29, 2013

Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma … – OneMedPlace (blog)

Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma …
OneMedPlace (blog)
An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their …
Clearing The Air On The Sanofi-Regeneron Asthma Drug TrialSeeking Alpha

all 2 news articles »

View full post on asthma – Google News

November 11, 2012

Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.

Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.

Drug Des Devel Ther. 2012;6:317-22

Authors: Xiao HT, Liao Z, Tong RS

Abstract
BACKGROUND: The aim of this review was to evaluate and summarize the available scientific information on penehyclidine hydrochloride (PHC) for the treatment of chronic obstructive pulmonary disease (COPD) as a result of its ability to attenuate Toll-like receptors. Penehyclidine hydrochloride is an anticholinergic drug manufactured in China, with both antimuscarinic and antinicotinic activity. PHC is used widely in the clinic as a reversal agent in cases of organic phosphorus poisoning and soman poisoning, but also may also have an important role as a bronchodilator in the treatment of obstructive airway disease, including asthma and, in particular, COPD.
METHODS: Our bibliographic sources included the CAPLUS, MEDLINE, REGISTRY, CASREACT, CHEMLIST, CHEMCATS, and CNKI databases, updated to September 2012. In order to assess the data in detail, we used the search terms “penehyclidine hydrochloride,” “COPD,” “muscarinic receptor,” and “toll-like receptors.” Papers were restricted to those published in the English and Chinese languages, and to “paper” and “review” as the document type. Patents were also reviewed.
RESULTS: Our survey mainly yielded the results of research on PHC and the mechanisms of COPD. COPD is a preventable and treatable disease with some significant extrapulmonary manifestations that may contribute to its severity in some patients. Recently, it has been shown that muscarinic receptors may interact with Toll-like receptors. Basic and clinical studies of the relationship between the mechanism of action and the effects of PHC in the respiratory tract have been studied by a number of laboratories and institutions. The main advantages of PHC are that it has few M(2) receptor-associated cardiovascular side effects and attenuates Toll-like receptors.
CONCLUSION: PHC may be a promising candidate agent in the treatment of COPD in the future because of its ability to attenuate Toll-like receptors. This review should be of help to those intending to research this topic further.

PMID: 23139625 [PubMed – in process]

View full post on pubmed: asthma

January 2, 2012

15-Lipoxygenase eicosanoids are the putative ligands for vanilloid receptors and peroxisome proliferator-activated receptors (PPARs).

15-Lipoxygenase eicosanoids are the putative ligands for vanilloid receptors and peroxisome proliferator-activated receptors (PPARs).

Proc Natl Acad Sci U S A. 2011 Dec 29;

Authors: Mabalirajan U, Agrawal A, Ghosh B

PMID: 22207620 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

November 1, 2010

Bitter Taste Receptors Found in Lungs May Aid Asthma Patients (HealthDay)

HealthDay – SUNDAY, Oct. 24 (HealthDay News) — Bitter taste receptors are located
in the lungs as well as on the tongue, a finding that might lead to
improved treatments for asthma and other obstructive lung diseases,
according to researchers at the University of Maryland School of Medicine
in Baltimore.

View full post on Yahoo! News: Health News

October 29, 2010